Bio Impact Capital LLC Verve Therapeutics, Inc. Transaction History

Bio Impact Capital LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	SELL	$8.84 - $18.7 $1.94 Million - $4.11 Million	-219,777 Reduced 25.62%	638,163 $8.9 Million
Q2 2023 Aug 14, 2023	BUY	$13.34 - $19.9 $726,216 - $1.08 Million	54,439 Added 6.78%	857,940 $16.1 Million
Q1 2023 May 12, 2023	SELL	$14.3 - $24.01 $73,788 - $123,891	-5,160 Reduced 0.64%	803,501 $11.6 Million
Q4 2022 Feb 14, 2023	BUY	$17.85 - $40.7 $3.09 Million - $7.04 Million	172,869 Added 27.19%	808,661 $15.6 Million
Q3 2022 Nov 14, 2022	BUY	$15.63 - $41.49 $9.94 Million - $26.4 Million	635,792 New	635,792 $21.8 Million

186

73.3M

85K

215K

Ticker VERV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,942,300
Market Cap $291M
Description
Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program t...

Get notified when there are updates to the investment portfolio of Bio Impact Capital LLC, based on Form 13F filings with the SEC.

Stay updated on Bio Impact Capital LLC with notifications on news.